Free Trial

Fulgent Genetics Q1 2023 Earnings Report

Fulgent Genetics logo
$18.34 -0.41 (-2.19%)
(As of 12/20/2024 05:16 PM ET)

Fulgent Genetics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

Fulgent Genetics Revenue Results

Actual Revenue
$66.17 million
Expected Revenue
$61.95 million
Beat/Miss
Beat by +$4.22 million
YoY Revenue Growth
N/A

Fulgent Genetics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Fulgent Genetics Earnings Headlines

Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Fulgent Genetics price target lowered to $22 from $26 at Piper Sandler
See More Fulgent Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fulgent Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulgent Genetics and other key companies, straight to your email.

About Fulgent Genetics

Fulgent Genetics (NASDAQ:FLGT), together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

View Fulgent Genetics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings